---
document_datetime: 2026-01-07 09:06:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/trazimera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: trazimera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5580109
conversion_datetime: 2026-01-10 11:34:47.682274
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Trazimera

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type II /  | This was an application for a group of | 11/12/2025                          |                                             | Annex II                         | Annex II has been updated as follows: Addition |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000288061   | variations. B.I.c.3 Change immediate - B.I.c.3.c   | the alternative site (Samsung Biologics Co. Ltd., 300, Songdo bio-daero, Yeonsu-gu, Incheon, 21987, Republic of Korea) under the section 'Name and address of the manufacturer(s) of the biological active substance(s)'   |
|---------------------|----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |                       |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------------|
| Variation type IA / EMA/VR/0000248147 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 03/02/2025 | SmPC, Annex II and PL |